Innovative Antibiotic Therapies for Carbapenem-Resistant Gram-Negative Bacterial Infections: Clinical Efficacy, Safety, and Comparative Studies
Microorganisms · 29.01.2025 · 13 (2) · 295
DOI: 10.3390/microorganisms13020295 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Microorganisms, online erschienen am 29.01.2025. Verfasst von Majid Eslami und 8 weiteren Autor:innen. Beteiligte Einrichtung: Cancer Research Center, Semnan University of Medical Sciences, Semnan 35147-99442, Iran. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 62 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
This review provides an overview of recent research and advancements in infection prevention and the treatment of drug-resistant bacterial diseases. Cefiderocol, a novel siderophore cephalosporin, has demonstrated effectiveness against carbapenem-resistant bacteria such as Pseudomonas aeruginosa and Acinetobacter baumannii. Clinical trials, including APEKS-NP and CREDIBLE-CR, affirm its efficacy for hospital-acquired pneumonia (HAP) but highlight concerns over increased mortality due to severe renal complications. Cefiderocol has shown superior outcomes in complicated urinary tract infections (cUTI) compared to imipenem–cilastatin. A comparison of colistin monotherapy versus combination therapy with meropenem for carbapenem-resistant infections revealed no significant improvement in clinical outcomes with combination therapy but noted delays in resistance development. Colistin–rifampicin combination therapy showed potential benefits for colistin-resistant Acinetobacter baumannii, although results were not statistically significant. SPR206, a polymyxin derivative, and durlobactam, a β-lactamase inhibitor, show promise in addressing these resistant strains, with durlobactam demonstrating efficacy in combination with sulbactam and imipenem–cilastatin. Additional studies investigated antibiotic strategies for resistant infections, including cefoperazone–sulbactam versus combination therapy with tigecycline, and examined infection-prevention strategies in surgical settings, comparing chlorhexidine–alcohol and povidone–iodine. This research highlights the importance of optimizing treatment regimens and infection-control measures across various healthcare settings, including neonatology and surgical care.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Cancer Research Center, Semnan University of Medical Sciences, Semnan 35147-99442, Iran.
- Department of Bacteriology and Virology, Faculty of Medicine, Semnan University of Medical Sciences, Semnan 35147-99442, Iran.
- Department of General Surgery, Yasuj University of Medical Sciences, Yasuj 75917-41417, Iran.
- Student Research Committee, Semnan University of Medical Sciences, Semnan 35147-99442, Iran.
- Faculty of Medicine, University of Bergen, 5020 Bergen, Norway.
ORCID-Profile: Majid Eslami, Seyedeh Zahra Banihashemian, Sahar Nikjoo Niaragh, Mohammad Amin Hemmati, Valentyn Oksenych
Zitieren
APA
Eslami, M., Safaripour, A., Banihashemian, S. Z., Nikjoo Niaragh, S., Hemmati, M. A., Shojaeian, A., Fakhariyan, S., Rabbani, A., & Oksenych, V. (2025). Innovative Antibiotic Therapies for Carbapenem-Resistant Gram-Negative Bacterial Infections: Clinical Efficacy, Safety, and Comparative Studies. Microorganisms, 13(2), 295. https://doi.org/10.3390/microorganisms13020295
Vancouver
Eslami M, Safaripour A, Banihashemian SZ, Nikjoo Niaragh S, Hemmati MA, Shojaeian A, et al. Innovative Antibiotic Therapies for Carbapenem-Resistant Gram-Negative Bacterial Infections: Clinical Efficacy, Safety, and Comparative Studies. Microorganisms. 2025;13(2):295. doi:10.3390/microorganisms13020295
BibTeX
@article{Eslami2025,
author = {Eslami, Majid and Safaripour, Amirabbas and Banihashemian, Seyedeh Zahra and Nikjoo Niaragh, Sahar and Hemmati, Mohammad Amin and Shojaeian, Arefeh and Fakhariyan, Setayesh and Rabbani, Atiye and Oksenych, Valentyn},
title = {Innovative Antibiotic Therapies for Carbapenem-Resistant Gram-Negative Bacterial Infections: Clinical Efficacy, Safety, and Comparative Studies},
journal = {Microorganisms},
year = {2025},
volume = {13},
number = {2},
pages = {295},
doi = {10.3390/microorganisms13020295}
}
EUVIMED